Sign in
TerminatedNo phase

Transnasal Induction of Normothermia for Neurogenic Fever

Key facts

Who runs it
CoolTech LLC
Where
Baltimore, United StatesSee the site
Trial code
Status
Terminated
People taking part
9 people enrolled
Started
21 Nov 2023
Ended
30 Nov 2025
Type of study
Interventional
Treatments tested
  • Transnasal Thermal Regulating Device
Record updated
26 January 2026
Why it stopped
Insufficient accrual

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (23)Hide the full registry criteria

Who can take part

  • Admitted to an Intensive Care Unit for a planned stay of at least 24 hours with a diagnosis of ischemic or hemorrhagic stroke, seizure, or metabolic encephalopathy
  • Ages 18-85 years, inclusive
  • Patient has fever ≥ 38.3°C and ≤ 38.9°C at the time of treatment initiation
  • Patient is orally intubated or has tracheostomy tube and is mechanically ventilated
  • Glasgow Coma Scale score of 3-11, inclusive
  • Must have informed consent from the patient or the legally authorized representative (LAR) making decisions for the patient

Who cannot take part

  • Prior skull-base surgery
  • Patient is in airborne/droplet disease isolation protocol
  • Any condition for which transnasal air flow would be contraindicated
  • Intubation is contraindicated
  • Weight of ≤ 100lb or ≥ 250lb
  • Active/ongoing epistaxis
  • Known or suspected pregnancy
  • Participation in another ongoing investigational study
  • Prisoners and/or patients for whom no LAR is available
  • Patient is or suspected to be immunocompromised
  • Nasal septal deviations (per standard of care CT scan; any degree)
  • Chronic rhinosinusitis
  • Traumatic brain injury
  • Penetrating cranial trauma
  • Recent nasal trauma or anterior base skull fracture
  • Refractory hypoxemia (partial pressure of oxygen in arterial blood (paO2) below 60 torr or oxyhemoglobin saturation below 90% despite endotracheal intubation, mechanical ventilation, and provision of supplemental oxygen of up to 0.60)
  • Refractory hypercarbia (partial pressure of carbon dioxide in arterial blood (paCO2) above 50 torr despite endotracheal intubation and conventional mechanical ventilation)

Where in United States

  • University of Maryland Medical CenterBaltimore, United States

About the trial

What the trial wants to find out

The objective of this study is to evaluate the efficacy of the COOLSTAT® Transnasal Thermal Regulating Device in reducing temperature in a population of febrile subjects who meet the inclusion/exclusion criteria.

The group in the trial

  • Transnasal Thermal Regulating DeviceTreatment being tested

    Consented subjects who develop fever will undergo cooling via transnasal thermal regulating device for a period of 24 hours

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Open Label Clinical Trial to Evaluate the Safety and Efficacy of the COOLSTAT® Transnasal Thermal Regulating Device in Inducing Normothermia for Neurogenic Fever in an Intensive Care Setting
Record updated
26 January 2026